{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:05:50Z","timestamp":1794027950283,"version":"4.8.0"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>Hematopoietic stem cell transplantation (HSCT) can cure malignant and nonmalignant hematological disorders. From 1983 to 2022, Taiwan performed more than 10,000 HSCT transplants. The Taiwan Blood and Marrow Transplantation Registry collects clinical information to gather everyone\u2019s experience and promote the advances of HSCT in Taiwan to gather everyone\u2019s experience and promote advances of HSCT in Taiwan. Compared with matched sibling donors, transplants from matched unrelated donors exhibited a trend of superior survival. In Taiwan, transplant donors showed remarkable growth from unrelated (24.8%) and haploidentical (10.5%) donors. The number of older patients (17.4%; aged \u226561 years) who underwent transplantation has increased markedly. This review summarizes several significant developments in HSCT treatment in Taiwan. First, the use of Anti-thymocyte globulin (ATG) and intravenous busulfan regimens were important risk factors for predicting hepatic sinusoidal obstruction syndrome. Second, a new, machine learning-based risk prediction scoring system for posttransplantation lymphoproliferative disorder has identified five risk factors: aplastic anemia, partially mismatched related donors, fludarabine use, ATG use, and acute skin graft-versus-host disease. Third, although the incidence of idiopathic pneumonia syndrome was low (1.1%), its mortality rate was high (58.1%). Fourth, difficult-to-treat mantle cell and T-cell lymphomas treated with autologous HSCT during earlier remission had higher survival rates. Fifth, treatment of incurable multiple myeloma with autologous HSCT showed a median progression-free survival and overall survival of 46.5 and 70.4 months, respectively. Sixth, different haploidentical transplantation strategies were compared. Seventh, caution should be taken in administering allogeneic HSCT treatment in older patients with myeloid leukemia with a Charlson Comorbidity Index \u22653 because of a higher risk of nonrelapse mortality.<\/jats:p>","DOI":"10.4103\/tcmj.tcmj_276_23","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T18:01:56Z","timestamp":1711389716000},"page":"127-135","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Recent advancements in hematopoietic stem cell transplantation in Taiwan"],"prefix":"10.4103","volume":"36","author":[{"given":"Chi-Cheng","family":"Li","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan"},{"name":"Center of Stem Cell and Precision Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan"},{"name":"School of Medicine, Tzu Chi University, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier Cheng-Hong","family":"Tsai","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"Genome and Systems Biology Degree Program, National Taiwan University, Taipei, Taiwan"},{"name":"Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Han","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan"},{"name":"Center of Stem Cell and Precision Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan"},{"name":"Department of Clinical Pathology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tso-Fu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan"},{"name":"School of Medicine, Tzu Chi University, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"R1-20260504","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.2010.491","article-title":"Hematopoietic stem cell transplantation: A global perspective","volume":"303","author":"Gratwohl","year":"2010","journal-title":"JAMA"},{"key":"R2-20260504","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/S2352-3026(15)00028-9","article-title":"One million haemopoietic stem-cell transplants: A retrospective observational study","volume":"2","author":"Gratwohl","year":"2015","journal-title":"Lancet Haematol"},{"key":"R3-20260504","year":"2022","journal-title":"Annual Report of Blood and Marrow Transplantation Registry, TBMTR"},{"key":"R4-20260504","journal-title":"Buddhist Tzu Chi Stem Cells Center"},{"key":"R5-20260504","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1034\/j.1600-0609.2000.9r200.x","article-title":"Veno-occlusive disease of the liver after hemopoietic cell transplantation","volume":"64","author":"Carreras","year":"2000","journal-title":"Eur J Haematol"},{"key":"R6-20260504","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jceh.2014.10.002","article-title":"Sinusoidal obstruction syndrome (hepatic veno-occlusive disease)","volume":"4","author":"Fan","year":"2014","journal-title":"J Clin Exp Hepatol"},{"key":"R7-20260504","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"key":"R8-20260504","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"key":"R9-20260504","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/bmt.2015.52","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease: Current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"R10-20260504","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/hep.1840190515","article-title":"Veno-occlusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms","volume":"19","author":"Shulman","year":"1994","journal-title":"Hepatology"},{"key":"R11-20260504","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: Incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"R12-20260504","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","article-title":"The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade","volume":"17","author":"Carreras","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"R13-20260504","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00277-019-03604-2","article-title":"The incidence and risk factors of hepatic veno-occlusive disease after hematopoietic stem cell transplantation in Taiwan","volume":"98","author":"Lee","year":"2019","journal-title":"Ann Hematol"},{"key":"R14-20260504","first-page":"1113","article-title":"The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders","volume":"146","author":"Delecluse","year":"1995","journal-title":"Am J Pathol"},{"key":"R15-20260504","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF00838047","article-title":"Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD)","volume":"20","author":"Nalesnik","year":"1998","journal-title":"Springer Semin Immunopathol"},{"key":"R16-20260504","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2015-05-615872","article-title":"How i treat posttransplant lymphoproliferative disorders","volume":"126","author":"Dierickx","year":"2015","journal-title":"Blood"},{"key":"R17-20260504","first-page":"2208","article-title":"Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study","volume":"94","author":"Curtis","year":"1999","journal-title":"Blood"},{"key":"R18-20260504","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1182\/blood.V87.9.3633.bloodjournal8793633","article-title":"Malignant neoplasms following bone marrow transplantation","volume":"87","author":"Bhatia","year":"1996","journal-title":"Blood"},{"key":"R19-20260504","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-transplant lymphoproliferative disease (PTLD): Risk factors, diagnosis, and current treatment strategies","volume":"8","author":"Al-Mansour","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"R20-20260504","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1182\/blood-2009-07-143545","article-title":"How I treat EBV lymphoproliferation","volume":"114","author":"Heslop","year":"2009","journal-title":"Blood"},{"key":"R21-20260504","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.bbmt.2019.02.016","article-title":"Risk factors and predictive scoring system for post-transplant lymphoproliferative disorder after hematopoietic stem cell transplantation","volume":"25","author":"Fujimoto","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R22-20260504","doi-asserted-by":"crossref","first-page":"e2034","DOI":"10.1002\/onco.13969","article-title":"Validation of a post-transplant lymphoproliferative disorder risk prediction score and derivation of a new prediction score using a national bone marrow transplant registry database","volume":"26","author":"Lee","year":"2021","journal-title":"Oncologist"},{"key":"R23-20260504","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/bmt.2014.151","article-title":"Pulmonary complications in hematopoietic SCT: A prospective study","volume":"49","author":"Lucena","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"R24-20260504","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0272-5231(03)00121-7","article-title":"Pulmonary complications in bone marrow transplantation: A practical approach to diagnosis and treatment","volume":"25","author":"Yen","year":"2004","journal-title":"Clin Chest Med"},{"key":"R25-20260504","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ccm.2016.12.007","article-title":"Early onset noninfectious pulmonary syndromes after hematopoietic cell transplantation","volume":"38","author":"Vande Vusse","year":"2017","journal-title":"Clin Chest Med"},{"key":"R26-20260504","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ccm.2017.07.002","article-title":"Noninfectious acute lung injury syndromes early after hematopoietic stem cell transplantation","volume":"38","author":"Ahya","year":"2017","journal-title":"Clin Chest Med"},{"key":"R27-20260504","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1164\/rccm.2007-413ST","article-title":"An official American Thoracic Society research statement: Noninfectious lung injury after hematopoietic stem cell transplantation: Idiopathic pneumonia syndrome","volume":"183","author":"Panoskaltsis-Mortari","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"R28-20260504","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N Engl J Med"},{"key":"R29-20260504","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/bmt.2013.123","article-title":"Risk factor analysis of idiopathic pneumonia syndrome after allogeneic hematopoietic SCT in children","volume":"49","author":"Sano","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"R30-20260504","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/bmt.2011.260","article-title":"High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT","volume":"47","author":"Tizon","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"R31-20260504","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1378\/chest.10-2889","article-title":"Risk factors and outcome of pulmonary complications after autologous hematopoietic stem cell transplant","volume":"141","author":"Afessa","year":"2012","journal-title":"Chest"},{"key":"R32-20260504","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bmt.1703142","article-title":"Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation","volume":"28","author":"Afessa","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"R33-20260504","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1182\/bloodadvances.2019000143","article-title":"Allogeneic reactivity-mediated endothelial cell complications after HSCT: A plea for consensual definitions","volume":"3","author":"Pagliuca","year":"2019","journal-title":"Blood Adv"},{"key":"R34-20260504","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1182\/blood-2003-05-1597","article-title":"Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation","volume":"102","author":"Fukuda","year":"2003","journal-title":"Blood"},{"key":"R35-20260504","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s12185-022-03417-6","article-title":"Incidence and predictors of idiopathic pneumonia syndrome in hematopoietic stem cell transplant patients: A nationwide registry study","volume":"116","author":"Liu","year":"2022","journal-title":"Int J Hematol"},{"key":"R36-20260504","doi-asserted-by":"crossref","first-page":"50.","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: Progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"key":"R37-20260504","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00277-019-03803-x","article-title":"Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for improving survival of lymphoma report","volume":"99","author":"Jo","year":"2020","journal-title":"Ann Hematol"},{"key":"R38-20260504","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of the German high-grade Non-Hodgkin lymphoma study group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"R39-20260504","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: A phase 2 study from the Groupe d\u2019Etude des lymphomes de l\u2019Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"key":"R40-20260504","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the second Nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"key":"R41-20260504","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/bmt.2009.165","article-title":"Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: Retrospective analysis of the experience of the Fukuoka BMT group","volume":"45","author":"Numata","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"R42-20260504","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bjh.13167","article-title":"Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: A study of children and adolescents in Japan","volume":"168","author":"Fukano","year":"2015","journal-title":"Br J Haematol"},{"key":"R43-20260504","doi-asserted-by":"crossref","first-page":"5662.","DOI":"10.1038\/s41598-022-09539-5","article-title":"Stem cell transplant for mantle cell lymphoma in Taiwan","volume":"12","author":"Wang","year":"2022","journal-title":"Sci Rep"},{"key":"R44-20260504","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/s41409-018-0116-6","article-title":"Stem cell transplantation for T-cell lymphomas in Taiwan","volume":"53","author":"Hsu","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"R45-20260504","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","article-title":"International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation","volume":"117","author":"Cavo","year":"2011","journal-title":"Blood"},{"key":"R46-20260504","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in Myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"R47-20260504","doi-asserted-by":"crossref","first-page":"e0167227.","DOI":"10.1371\/journal.pone.0167227","article-title":"Prevalence and mortality-related factors of multiple Myeloma in Taiwan","volume":"11","author":"Chen","year":"2016","journal-title":"PLoS One"},{"key":"R48-20260504","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/cncr.22850","article-title":"Epidemiology of multiple myeloma in Taiwan: Increasing incidence for the past 25 years and higher prevalence of extramedullary Myeloma in patients younger than 55 years","volume":"110","author":"Huang","year":"2007","journal-title":"Cancer"},{"key":"R49-20260504","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jfma.2018.07.020","article-title":"Autologous stem cell transplantation in multiple myeloma: Post-transplant outcomes of Taiwan blood and marrow transplantation registry","volume":"118","author":"Huang","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"R50-20260504","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R51-20260504","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2012.06.019","article-title":"Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: Results of a prospective phase II trial","volume":"18","author":"Solomon","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"R52-20260504","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.bbmt.2014.02.001","article-title":"Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide","volume":"20","author":"Castagna","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"R53-20260504","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.bbmt.2018.07.008","article-title":"Reduced-intensity conditioning and dual T lymphocyte suppression with antithymocyte globulin and post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplants for hematological malignancies","volume":"24","author":"Law","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R54-20260504","doi-asserted-by":"crossref","first-page":"5871.","DOI":"10.1182\/blood.V128.22.5871.5871","article-title":"Addition of ATG to myeloablative haplo conditioning with post-transplantation cyclophosphamide might decrease the risk of Gvhd and TRM without increasing the risk of relapse","volume":"128","author":"Al Dawsari","year":"2016","journal-title":"Blood"},{"key":"R55-20260504","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood.V98.12.3456","article-title":"Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide","volume":"98","author":"Luznik","year":"2001","journal-title":"Blood"},{"key":"R56-20260504","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood"},{"key":"R57-20260504","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2005-05-2146","article-title":"Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched\/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation","volume":"107","author":"Lu","year":"2006","journal-title":"Blood"},{"key":"R58-20260504","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bmt.1705445","article-title":"Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies","volume":"38","author":"Huang","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"R59-20260504","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.seminhematol.2016.01.004","article-title":"Haploidentical stem cell transplantation: Anti-thymocyte globulin-based experience","volume":"53","author":"Chang","year":"2016","journal-title":"Semin Hematol"},{"key":"R60-20260504","doi-asserted-by":"crossref","first-page":"1097.","DOI":"10.3390\/cancers14041097","article-title":"Outcomes of different haploidentical transplantation strategies from the Taiwan blood and marrow transplantation registry","volume":"14","author":"Tsai","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R61-20260504","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","article-title":"Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute Myeloid leukemia in first complete remission or with myelodysplastic syndrome","volume":"28","author":"McClune","year":"2010","journal-title":"J Clin Oncol"},{"key":"R62-20260504","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2009.21.8073","article-title":"Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia","volume":"28","author":"Lim","year":"2010","journal-title":"J Clin Oncol"},{"key":"R63-20260504","doi-asserted-by":"crossref","first-page":"850.","DOI":"10.1186\/s12885-015-1857-x","article-title":"The impact of comorbid disease history on all-cause and cancer-specific mortality in Myeloid leukemia and myeloma \u2013 A Swedish population-based study","volume":"15","author":"Mohammadi","year":"2015","journal-title":"BMC Cancer"},{"key":"R64-20260504","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3324\/haematol.2014.107557","article-title":"Hematologic malignancies in elderly patients","volume":"99","author":"Hassan","year":"2014","journal-title":"Haematologica"},{"key":"R65-20260504","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"R66-20260504","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.jfma.2020.12.021","article-title":"Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome","volume":"120","author":"Chien","year":"2021","journal-title":"J Formos Med Assoc"}],"container-title":["Tzu Chi Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_276_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:31:28Z","timestamp":1787769088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_276_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/tcmj.tcmj_276_23","relation":{},"ISSN":["1016-3190","2223-8956"],"issn-type":[{"value":"1016-3190","type":"print"},{"value":"2223-8956","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"assertion":[{"value":"2023-10-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}